Otros idiomas NanoVibronix, Inc.

Acciones

NAOV

US63008J6038

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 28/06/2024			Varia. Cinco días.	Varia. 1 de enero.
0,7 ^USD	-1,80 %		-4,77 %	-39,13 %

22/05	NanoVibronix, Inc. anuncia el inicio del estudio clínico de UroShield en la Universidad de Michigan	CI
15/05	NanoVibronix, Inc. presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan	22/05
NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan	22/05
NanoVibronix Issues Letter to Stockholders	16/05
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
NanoVibronix Signs Multiyear Distribution Deal With CB Medical for UroShield	14/05
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield	14/05
NanoVibronix, Inc. Announces Distribution Agreement with Cb Medical, Llc for the Distribution of Uroshield	14/05
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs’ FSS Contract Award	01/05
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs? FSS Contract Award	01/05
NanoVibronix : Failure to Satisfy Listing Rule - Form 8-K	15/04
NanoVibronix Issues Letter to Stockholders	09/04
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield	28/03
NanoVibronix Featured in Your Bladder Health Magazine	06/12
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	04/12
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	04/12
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan	28/11
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan	28/11
NanoVibronix Regains Nasdaq Compliance	21/11
NanoVibronix Issues Letter to Shareholders	14/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas NanoVibronix, Inc.

Acciones

NAOV

US63008J6038

Otros idiomas

Filtros